Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 6/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | LIPA | P38571 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23804677 | 0.97 | NPC1 (0.44) | SMN1; SMN2PDE7BHTTHPGDTSHR | |
| SCHEMBL1860727 | 0.86 | PIK3CA (0.44) | SMN1; SMN2HPGDPIK3CDPARP1PIK3CA | |
| SCHEMBL23815518 | 0.86 | NPY5R (0.44) | SMN1; SMN2PDE7BHTTHPGDTSHR | |
| SCHEMBL1858883 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1859229 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2HTTHPGDPIK3CDPARP1 | |
| SCHEMBL1856157 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDPIK3CAPIK3CBMTOR | |
| SCHEMBL23804783 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDPIK3CAPIK3CBMTOR | |
| SCHEMBL23804760 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2HTTTSHRPIK3CAPIK3CB | |
| SCHEMBL19142982 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2PIK3CARAB9ANPC1POLB | |
| SCHEMBL21135267 | 0.75 | PIKFYVE (0.40) | SMN1; SMN2PDE7BHTTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4118087-A1 | SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022261068-A1 | METHODS AND TREATMENT OF VIRAL INFECTION WITH SUBSTITUTED FURO-PYRIMIDINES | Verge Analytics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021183439-A1 | SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021183439-A1 | SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146395-A1 | Substituted Pyrimidines and Uses Thereof | PIKFYVE, PIK3CA, PIK3CB | SMN1; SMN2 170/4885PDE7B 758/4885HTT 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.